Kornimate/medical-research-clean huggingface dataset:
grow (glioma specialists reaching out with support) support

Conditions: Low-grade Glioma; Survivorship; Care Giving Burden

Summary: this research study is being done to test a participant and caregiver-driven model of follow-up survivorship care,grow support (glioma specialists reaching out with support), for post-treatment, low grade glioma patients.

this research study is a feasibility study, which examines if a supportive intervention for people with low grade gliomas (lggs) and their caregivers is acceptable and feasible to patients and their caregivers. the research study procedures include: screening for eligibility and study interventions including filling out questionnaires and virtual or in-clinic supportive follow up visits to identify additional supportive needs that may arise. participants will be in this research study for up to 6 months. it is expected that about 40 people will take part in this research study. the levitan-zabin fund for grow support is supporting this research study by providing funds for research team members to do this study.

Eligibility criteria:
inclusion criteria: * patient inclusion criteria include: * must be at least 18 years of age; * diagnosed with low grade glioma (who grade 1 or 2) * completed active treatment within the last 2 years and are undergoing surveillance follow-up * must have at least one caregiver willing to participate as indicated below * read and comprehend english such that they are able to complete required intervention sessions and psychosocial battery in english and are able to understand and willing to sign an electronic informed consent document. * confirms willingness to undergo initial and follow-up questionnaire battery. * caregiver inclusion criteria include: * must be at least 18 years of age * read and comprehend english such that they are able to complete required intervention sessions and psychosocial battery in english and able to understand and willing to sign an electronic informed consent document * consider themselves personally involved in the patient's care and decisions about the care they receive. exclusion criteria: * bipolar disorder, * psychotic disorders and * confusion or altered mental state that would prohibit understanding and giving of informed consent. however, if the patient's bipolar disorder or psychotic disorder is currently treated/managed, the patient will be eligible for the study.

Keywords: low-grade glioma survivorship care giving burden
adaptive optics imaging of outer retinal diseases

Conditions: Retinal Degeneration; Age-Related Macular Degeneration; Retinitis Pigmentosa; Hydroxychloroquine Retinopathy; Usher Syndromes; Late-Onset Retinal Degeneration; Cone Dystrophy; Cone Rod Dystrophy; Rod Cone Dystrophy; Rod Dystrophy

Summary: the objective of the study is to collect adaptive optics (ao) retinal images from human subjects with outer retinal diseases (diseases of the outer retina including photoreceptor, retinal pigment epithelium (rpe), basement membrane or choroidal pathologies) to develop new diagnostic methods, biomarkers, and clinical endpoints.

objective: the objective of the study is to collect adaptive optics (ao) retinal images from human subjects with outer retinal diseases (diseases of the outer retina including photoreceptor, retinal pigment epithelium (rpe), basement membrane or choroidal pathologies) to develop new diagnostic methods, biomarkers, and clinical endpoints. study population: up to fifty (50) healthy volunteers without eye disease (cohort 1) and up to fifty (50) affected participants with any type of outer retinal disease (cohort 2) will be enrolled. design: this is a longitudinal study protocol where participants will be imaged with investigational multimodal ao (mao) retinal imaging systems that include optical coherence tomography (oct) and scanning laser ophthalmoscopy (slo) channels over three years. high resolution oct and slo videos will be collected while the instruments automatically detect and correct for image distortion caused by ocular aberrations. in general, videos of different retinal cellular structures will be acquired from several retinal locations using various imaging modes. outcome measures: the primary outcomes for this protocol are development of new diagnostic methods and disease biomarkers, investigation of cellular morphological and functional changes due to various outer retinal diseases, and development of new ao clinical endpoints for novel therapies.

Eligibility criteria:
inclusion criteria: 1. are 21 years of age or older, 2. have the ability to cooperate with instructions during adaptive optics imaging (similar to instructions given during a clinical eye exam), 3. have the ability to understand and sign an informed consent. (non-english speaking participants will not be enrolled into the study), and 4. have been diagnosed with outer retinal disease or condition (cohort 2). exclusion criteria: 1. have a condition which prevents adequate images from being obtained (e.g. unstable fixation or media opacity), 2. have visual correction outside of the range +4 diopters (d) to -8 d, 3. have a history of adverse reaction to mydriatic drops, 4. have a predisposition to (i.e., narrow iridocorneal angle) or any history of acute angle closure glaucoma (aacg), or 5. are working under the direct supervision of drs. hammer, cukras and liu, or any of the nih/nei ais.
effectiveness of robot-assisted upper-limb exercise in cervical sci

Conditions: Cervical Vertebrae Injury

Summary: the aim of the project is to test the effectiveness of robot-assisted upper-limb exercise in persons after cervical spinal cord injury. in a randomised controlled two-arm trial, the effect of adding two types of robot-assisted upper-limb exercise to standard occupational therapy will be tested. three primary and two secondary outcomes will be assessed using well-established measures.

unlike for persons after stroke, there is no high-quality evidence of the effectiveness of robot-assisted upper-limb exercise in persons after cervical spinal cord injury. for this reason, we are aiming to conduct a randomised trial. the trial will involve two groups of adult patients admitted to inpatient rehabilitation. one group will receive standard occupational therapy, tailored to the patient's needs and abilities, five times per week for 90 minutes. in addition to the standard occupational therapy, the other group will receive ten 30-minute session of robot-assisted exercise: five sessions of exercise for fingers and hand using a specialised device, and five sessions of gross-motor exercise using an exoskeleton. three outcome measures will be used to comprehensively assess the patients at the beginning and at the end of the intervention, i.e., upon admission and discharge: the graded redefined assessment of strength, sensibility and prehension (grassp; general and myelopathy version), the spinal cord independence measure (scim), and the canadian occupational performance measure (copm). the progress in those measures will be compared between the two groups.

Eligibility criteria:
inclusion criteria: * ability to move unloaded upper limbs * at least 18 years of age * ability to sit for one hour * ability to understand the instructions for robot-assisted exercise exclusion criteria: * inability to sit for one hour * presence of hospital-acquired infection that requires isolation * bodily impairment other than spinal cord injury * inability to understand the instructions for robot-assisted exercise

Keywords: spinal cord injury upper limbs impairment rehabilitation
treatment of acute myeloblastic leukemia in younger patients

Conditions: Acute Myeloblastic Leukemia

Summary: study of the value of the cytogenetics and the monitoring of the residual minimum disease in the standard treatment of acute myeloblastic leukemia.

the treatment scheme is purely welfare and therefore it does not require any approval of ethical committees for his application. it gathers the basic ideas of the present treatment of the aml, with optional induction according to preference of each center with daunorubicin or idarubicin (x3) associated to arac (x7). the patients who reach cr consolidate with an identical cycle to the used one in the induction. later (if pte has identical donor hla, and as much it as their doctors has preference by this option) receive allogenic transplant. the other patients who reach cr receive two intensifications, one that arac to intermediate dose contains and another one with autologous transplant, previous preparation with busulfán, etoposide and arac. later all antileucemic treatment is suspended until possible relapse. this scheme of treatment is accompanied by a valuation of the quality of the cr with traditional morphology, immunocytometry and molecular genetic study and of a pursuit of residual minimum disease (emr) using the same techniques.

Eligibility criteria:
inclusion criteria: * age\< or =65 years. * ecog\<=3. * aml of new diagnose. * consent for chemotherapy.

Keywords: acute myeloblastic leukemia
phase 3, febuxostat, allopurinol and placebo-controlled study in gout subjects.

Conditions: Gout

Summary: the purpose of this study is to compare febuxostat, allopurinol and placebo, once daily (qd), in subjects with gout.

a phase 3 study comparing 80 mg, 120 mg or 240 mg of febuxostat, allopurinol (300 mg for those with normal renal function and 100 mg for those with impaired renal function) and placebo administered once daily in subjects with gout. subjects will receive treatment for 28 weeks.

Eligibility criteria:
inclusion criteria: * hyperuricemia (serum urate ≥8.0 mg/dl and gout by american rheumatism association criteria * renal function defined as a serum creatinine level of \ 20 milliliters per minute (ml/min) by cockroft and gault formula. exclusion criteria: * history of xanthinuria * intolerance to allopurinol * presence of renal calculi, * alcohol intake of ≥ 14 drinks/week * clinically significant medical condition

Keywords: uric acid, gout, xanthine oxidase, febuxostat, tophi
a post marketing observational study of the safety and efficacy of elonva (corifollitropin alfa) in general practice (p08165)

Conditions: Infertility, Female

Summary: this observational study will examine the safety and efficacy profile of elonva (corifollitropin alfa) when administered in korean women undergoing controlled ovarian stimulation (cos) in combination with a gonadotropin-releasing hormone (gnrh) antagonist for the development of multiple follicles in an assisted reproductive technology (art) program.


Eligibility criteria:
inclusion criteria: - women with an indication for cos prior to in vitro fertilization (ivf)/intracytoplasmic sperm injection (icsi) who meet the criteria as mentioned in the current korean elonva local label exclusion criteria: * hypersensitivity to the active substance or to any of the excipients * tumors of the ovary, breast, uterus, pituitary or hypothalamus * abnormal (not menstrual) vaginal bleeding without a known/diagnosed cause. * primary ovarian failure * ovarian cysts or enlarged ovaries * a history of ohss * a previous cos cycle that resulted in more than 30 follicles ≥ 11 mm measured by ultrasound examination * basal antral follicle count \> 20 * fibroid tumors of the uterus incompatible with pregnancy * malformations of the reproductive organs incompatible with pregnancy * pregnancy * polycystic ovarian syndrome
youth mhealth adherence intervention for hiv+ ymsm

Conditions: HIV

Summary: this study will help determine feasibility, acceptability, and preliminary efficacy of an app for hiv medication adherence over a 3-month period. participation is 3 months consisting of two study visits: an initial study visit and a 3 month follow up visit with both visits lasting about 60-90 minutes. the participant must use the study application (app) at least once daily, and at study visits, must complete surveys.

young men who have sex with men (ymsm) are disproportionately affected by hiv in the us and fewer than half of youth who are prescribed antiretroviral therapy (art) achieve viral suppression. yet few interventions have been developed to address adherence in this population with unique developmental/psychosocial needs. mobile technology, which is constantly consumed by youth, has the potential to deliver interventions that provide support and feedback in real time as youth go about their daily lives. this pilot study will test a theory-driven, patient-centered, mobile phone-based intervention (mhealth app) targeting medication adherence among hiv+ youth. it is a three-month prospective feasibility trial to test a medication adherence mobile application consisting of two study visits: baseline and 3-month follow up. data collection consists of app usage, computer assisted self-interview (casi) for participant satisfaction with the app, demographics, and mental health and risk behaviors, as well as medical chart abstraction of disease biomarkers (cd4, viral load) and pharmacy refill data.

Eligibility criteria:
inclusion criteria: 1. males (sex at birth male) age 14 to 24 years. 2. hiv-positive 3. owns an android smart phone 4. within 1-month of initiating antiretroviral therapy (art) medication, previously failed art and about to restart an art regimen, or currently on art having trouble with adherence (defined as having a detectable viral load above 200 copies/ml). 5. msm (men who have sex with men) 6. receiving care at the children's hospital of philadelphia (chop) adolescent hiv clinic at the time of the study exclusion criteria: 1. females (sex at birth; not gender) 2. males age 13 years or younger or 25 years and older. 3. hiv-negative or status unknown 4. not in care at the chop adolescent hiv clinic at the time of the study. 5. does not own an android smart phone (iphone, blackberry, etc. phone users) 6. is already art adherent (defined as having an undetectable or suppressed, \<200 copies/ml, viral load) or is not on or going to be on art during the study period.

Keywords: men who have sex with men (msm) mhealth antiretroviral therapy (art) native android app
comparison of microplastic levels in placenta and cord blood samples of pregnant women with fetal growth retardation and healthy pregnant women

Conditions: Microplastic Levels in Placenta and Cord Blood

Summary: in this study, microplastic levels in the placenta and cord blood of pregnant women with fetal growth retardation and healthy pregnant women will be compared in placenta and cord blood samples after delivery.

the study will be conducted with a total of 40 pregnant women, 20 of whom are in the control groups and those with fgr diagnoses. cases in both groups will be matched in terms of demographic information. demographic information (including socioeconomic status, educational level, region of residence), ultrasound and doppler examination results, newborn weight at birth, apgar score, gender, mode of delivery, whether there is a need for neonatal intensive care or not will be recorded.

Eligibility criteria:
inclusion criteria: * between the ages of 18-40 years * gestational age between 320/7 - 396/7 weeks * singleton pregnancy * for the fgr group: estimated fetal weight \<10th percentile * for the control group: being healthy pregnant * intact amniotic membrane exclusion criteria: -
tau pet outcomes with anti-amyloid immunotherapies

Conditions: Cognitive Impairment, Mild; Dementia, Mild; Alzheimer Disease

Summary: this is an imaging study of patients with mild alzheimer's disease receiving amyloid-targeting therapy and under the care of neurologists at mayo clinic in rochester, mn.


Eligibility criteria:
inclusion criteria * age 50-90 years * male or female * mild cognitive impairment due to ad or mild ad * amyloid positive via csf or pet * meets other eligibility criteria for anti-amyloid immunotherapy * subject or delegate provides informed consent exclusion criteria * subjects unable to lie down without moving for 10 minutes. * women who are pregnant or cannot stop breast feeding for 24 hours. * claustrophobic patients unable to tolerate the scans (no sedation can be offered).
a radiomic model for risk of local recurrence and dfs for t3 and t4 non-small cell lung cancer

Conditions: Lung Cancer, Nonsmall Cell

Summary: the investigators retrospectively collected the participants with t3 and t4, n0-2, m0 nsclc patients resected between january 2013 to december 2021 for training and internal validation. the clinical data, preoperative laboratory results and images were collected. high-risk margins were defined as r1 or r2 surgical margins or local recurrence during follow-up, and the investigators also collected the disease-free survival time. on the deepwise multi-modal research platform, the images were semi-automatically segmented and expanded outward by 3mm to obtain the peritumor tissue. pyradiomics was used to extract the radiomic features. lasso was used to select the features and tumor radiomics model, peritumor model and combined model were built using 5-fold cross-validation. and it was further tested on the independent cohort. discrimination was assessed by using the c-index and area under the receiver operating characteristic curve (auc), sensibility, specificity.


Eligibility criteria:
inclusion criteria: * patients with t3 and t4 stage nsclc； * available preoperative chest cte within two weeks of surgery exclusion criteria: * inadequate imaging quality resulted from breathing artifact; * without regularly follow-up information on recurrence location and time

Keywords: non-small cell lung cancer surgical margin dfs radiomics
efficacy study of two different strategies for restenosis in sirolimus-eluting stents

Conditions: Coronary Artery Disease

Summary: for lesions which develop restenosis after a drug-eluting stent, it is not known which the right strategy to use is, implantation of the same type of des as the initial one or a des with a different drug.

treatment of in-stent restenosis after implantation of a des has poorly been studied. although there are no data, it may be assumed that certain lesions might be resistant to a given drug and in need of a different des. thus, for lesions which develop restenosis after a des, it is not known which the right strategy to use is, implantation of the same type of des as the initial one or a des with a different drug. this prospective, randomized trial will compare the anti-restenotic efficacy of pes or ses in patients with restenosis after initial implantation of a ses

Eligibility criteria:
inclusion criteria: * patients older than age 18 with ischemic symptoms or evidence of myocardial ischemia in the presence of \> 50% re- stenosis after prior implantation of sirolimus eluting stents in native coronary vessels * written, informed consent by the patient or her/his legally-authorized representative for participation in the study * in women with childbearing potential a negative pregnancy test is mandatory exclusion criteria: * cardiogenic shock * acute myocardial infarction within the first 48 hours from symptom onset. * target lesion located in the left main trunk or bypass graft. * malignancies or other comorbid conditions (for example severe liver, renal and pancreatic disease) with life expectancy less than 12 months or that may result in protocol non-compliance. * allergy to antiplatelet therapy, sirolimus, paclitaxel, stainless steel. * pregnancy (present, suspected or planned) or positive pregnancy test. * previous enrollment in this trial. * patient's inability to fully comply with the study protocol.

Keywords: in-stent restenosis in-des-restenosis paclitaxel sirolimus
effectiveness of physiotherapy on postcesarean pain and functional activities

Conditions: Cesarean Section

Summary: this study aims to investigate the effectiveness of physiotherapy applications in early postcesarean problems.

this study aims to investigate the effectiveness of physiotherapy applications in early postcesarean problems which make difficulties in functional activities, and includes a physiotherapy intervention group and a control group. physical characteristics, obstetrical and surgical histories, and systemic problems, back pain, low back pain, headache, urinary/fecal incontinence problems and bowel habit of the subjects both in pregnancy and postpartum periods are recorded. first ambulation time after cesarean, presence of syncope, related vital signs, onset time of bowel peristalsis and defecation are also recorded. intensities of incisional pain and difficulty in performing functional activities are evaluated by daily 0-10 cm visual analogue scales (vass). also, intensities of back pain, low back pain, headache, bloated feeling of the abdomen, and fatigue are also evaluated by daily vass. physiotherapy program included breathing exercises, active joint movements of the lower limbs, posture exercises, connective tissue manipulation and transcutaneous electrical nerve stimulation.

Eligibility criteria:
inclusion criteria: cesarean section giving birth to single baby having cesarean under general anesthesia exclusion criteria: giving birth to multiple babies being followed in intensive care unit after cesarean because of complications

Keywords: postcesarean physiotherapy incisional pain functional activity connective tissue manipulation transcutaneous electrical nerve stimulation
rosie the chatbot: leveraging automated and personalized health information communication

Conditions: Pregnancy; Postpartum Depression; Infant Development; Infant Conditions

Summary: rosie the chatbot is an educational chatbot that moms can have on their computers or cellphones and will work by moms typing in their questions about pregnancy, health, infant milestones, and other variety of health related topics and receiving back a response immediately. rosie only provides information from verified sources such as children's hospitals, health organizations and government agencies. rosie does not ask moms to provide any personal information on her or her child, her chat is completely confidential, it works in english and spanish and will be free.

this study will examine whether the use of a chatbot to impart health information to minority women during pregnancy and postpartum period improves health care seeking behavior and maternal and infant health outcomes. this study does not involve administration of an investigational intervention and therefore poses minimal risk to participants. aim 1: develop technology for a "chatbot" that will provide health information support to vulnerable mothers the moment they need it. aim 2: evaluate the use of rosie on maternal and infant outcomes. aim 3: release an open-source packet for the construction of a chatbot. * participants in the study will be randomly assigned into one of two groups, rosie the chatbot group (treatment group) and book club group (control group). * participants in the rosie the chatbot group will be taking a pre-test health survey, mid-test health survey, and post-test health survey. in addition, they will be expected to actively use the chatbot app by asking questions related to maternal and infant health and selecting "thumbs up or thumbs down" to provide feedback for questions' response and use the features (video library, resources page, frequently asked questions (faq), and daily syllabus). * participants in the book club group will be taking a pre-test health survey, mid-test health survey, and post-test health survey. in addition, they will receive a monthly children's book, which they are expected to read with baby if parenting or individually if pregnant.

Eligibility criteria:
inclusion criteria: * age 14 years and older * racial minority women * pregnant or has an infant \< 6 months * must be able to read english or spanish exclusion criteria: * mother younger than 14 years of age at time of child's birth. * non-hispanic white

Keywords: chatbot health information racial/ethnic health disparities maternal and child health artificial intelligence question-answering models